AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 292: R625-R636, 2007. First published August 17, 2006; doi:10.1152/ajpregu.00418.2005
0363-6119/07 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/1/R625    most recent
00418.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thiesson, H. C.
Right arrow Articles by Skøtt, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thiesson, H. C.
Right arrow Articles by Skøtt, O.

WATER AND ELECTROLYTE HOMEOSTASIS

Renal sodium retention in cirrhotic rats depends on glucocorticoid-mediated activation of mineralocorticoid receptor due to decreased renal 11beta-HSD-2 activity

Helle C. Thiesson,1,2 Boye L. Jensen,1 Claus Bistrup,1,2 Peter D. Ottosen,3 Alison D. McNeilly,4 Ruth Andrew,4 Jonathan Seckl,4 and Ole Skøtt1

1Department of Physiology and Pharmacology, University of Southern Denmark, Odense; 2Laboratory of Nephropathology and 3Institute of Pathology, Odense University Hospital, Odense, Denmark; and 4Endocrinology Unit, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, Scotland

Submitted 13 June 2005 ; accepted in final form 25 July 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Downregulation of the renal glucocorticoid-metabolizing enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD-2) during liver cirrhosis may allow activation of the mineralocorticoid receptor (MR) by glucocorticoids and contribute to sodium retention. We tested this hypothesis in male Wistar rats with decompensated liver cirrhosis and ascites 7 wk after bile duct ligation (BDL). Renal 11beta-HSD-2 mRNA, protein, and activity were significantly decreased in decompensated rats. The urinary Na+/K+ ratio was reduced by 40%. Renal epithelial sodium channel (ENaC) mRNA and immunostaining were only slightly affected. Complete metabolic studies, including fecal excretion, showed that the BDL rats had avid renal sodium retention. Treatment of the BDL rats with dexamethasone suppressed endogenous glucocorticoid production, normalized total sodium balance and renal sodium excretion, and reduced ascites formation to the same degree as direct inhibition of MR with K-canrenoate. Total potassium balance was negative in the BDL rats, whereas renal potassium excretion was unchanged. In the distal colon, expression of ENaC was increased in BDL rats. Fecal potassium excretion was increased in cirrhotic rats, and this was corrected by treatment with K-canrenoate but not dexamethasone. We conclude that development of sodium retention and decompensation in cirrhotic rats is associated with downregulation of renal 11beta-HSD-2 activity and inappropriate activation of renal sodium reabsorption by endogenous glucocorticoids. In addition, the overall potassium loss in the BDL model is due to increased fecal potassium excretion, which is associated with upregulation of ENaC in distal colon.

aldosterone; renin; ascites; bile duct ligation

DECOMPENSATED LIVER CIRRHOSIS is characterized by avid sodium and water retention. Ascites formation is associated with a high morbidity, and in humans there is a mortality rate of 50% within 3 yr (3). In some patients, activation of the renin-angiotensin-aldosterone-system contributes to sodium retention (7, 35, 42), but many patients exhibit low or normal plasma renin and aldosterone concentrations (8, 18, 41, 43), leaving the sodium retention unexplained. Interestingly, studies in rats have demonstrated transient downregulation of the glucocorticoid-metabolizing enzyme 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD-2) in the kidney 2–4 wk after bile duct ligation (BDL), before cirrhosis and ascites develops (1, 10). Glucocorticoids and aldosterone bind with equal affinity to the mineralocorticoid receptor (MR) in vitro, and cortisol (in humans) and corticosterone in (rats ad mice) circulate at 100–1,000 times the level of aldosterone in plasma (11, 15). The selective access of aldosterone to the MR is ensured by 11beta-HSD-2, predominantly localized in epithelial mineralocorticoid target cells in the kidney and colon. 11beta-HSD-2 converts corticosterone and cortisol to their inactive 11-keto metabolites, 11-dehydrocorticosterone and cortisone, respectively. These findings led to the proposal that glucocorticoids could contribute to excess activation of MR with progression of liver cirrhosis (1, 10) and thereby mediate sodium retention and potassium loss. Consistent with this, loss-of-function mutations in the 11beta-HSD-2 gene (39) and inhibitors of 11beta-HSD-2 activity (38) lead to sodium retention.

Based on existing data, 11beta-HSD-2 expression and activity seem to be suppressed in the preascitic phase in the first 2–4 wk after BDL (1, 10). There are currently no data available on the potential changes in 11beta-HSD-2 activity and its contribution to the marked sodium retention that occurs in later stages of the disease when decompensation with ascites develops. More importantly, intervention has not been tested. The present study addressed directly the hypothesis that downregulation of 11beta-HSD-2 in distal nephron and/or colon contributes to sodium retention in BDL rats with decompensated liver cirrhosis. Rats were examined 5 and 7 wk after BDL, when they suffered from compensated and decompensated liver cirrhosis, respectively (6, 26). Plasma and tissue levels of the renin-angiotensin-aldosterone system components and of 11beta-HSD-2 were measured, and the findings were correlated with sodium and potassium total balance studies. In addition, the functional significance of endogenous glucocorticoids for sodium retention and potassium wasting was tested by suppression of endogenous glucocorticoids by treatment with the glucocorticoid receptor-specific agonist dexamethasone.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals and Surgical Protocol

Male Wistar rats were obtained from M & B (Ejby, Denmark). The Danish Animal Experiments Inspectorate approved all experimental procedures, and all animals were treated according to the Guide for the Care and Use of Laboratory Animals. The rats were fed a diet with 0.2% sodium and 1.0% potassium (Altromin 1324; Altromin International, Lage, Germany) and had free access to tap water. When rats were in metabolic cages, food was administered as granules (diameter 1.7 mm) to avoid spillage into feces and urine collection vials. Animals were anesthetized by subcutaneous injection with fentanyl citrate (0.25 mg/kg), fluanisone (8 mg/kg), and diazepam (4 mg/kg). The common bile duct was isolated and ligated, and 0.5 cm was excised (26) or manipulated and left intact (sham surgery). Postoperative pain was treated by administration of buprenorphin subcutaneously (0.1 mg/kg). We performed three experimental series in the present study.

At the end of the different treatment protocols, the rats were decapitated and trunk blood was collected. Organs were removed, weighed, and snap frozen for later RNA and protein isolation. Ascites volume was determined by aspiration of free fluid in the abdominal cavity.

Series 1: 5-wk BDL rats. In the first series, six rats had BDL and five rats were sham operated (sham). These rats were followed for 5 wk.

Series 2: 7-wk BDL rats. To study sodium balance in the decompensated phase, the next groups of rats were followed for 7 wk (BDL, n = 18; sham, n = 12). The rats were housed in individual metabolic cages from day 42 to day 49 after BDL. Na+, K+, and water intake and excretion were followed after a 2-day run-in period. Rats without ascites were excluded from analysis in this series.

Series 3: 7-wk BDL-intervention. In the third series, we tested the effect of dexamethasone and K-canrenoate on Na+ and K+ balance in decompensated BDL rats (sham-vehicle, n = 12; BDL + vehicle, n = 15; BDL + K-canrenoate, n = 15; BDL + dexamethasone, n = 15). Rats received vehicle, dexamethasone (100 µg·kg–1·day–1; Decadron, Merck Sharp & Dohme, Haarlem, The Netherlands), or K-canrenoate (80 mg·kg–1·day–1; Soldactone, Searle, Denmark) for 5 days in the decompensated stage with sodium retention (days 44–48). A 48-h run-in period in metabolic cages was allowed before administration of drugs. Balance studies began 24 h before drug administration. The experiment was terminated at 7 wk (day 49) after BDL. Rats that did not complete the basal 24-h collections were excluded from the data analysis.

Plasma and Urine Analyses

Plasma renin and atrial natriuretic peptide (ANP) concentrations were measured by radioimmunoassay as described previously (9, 29). Plasma aldosterone and corticosterone concentrations were measured with commercial kits (Coat-A-Count Aldosterone, DPC, Los Angeles, CA; rat corticosterone assay, Amersham Biotrak, Amersham, Buckinghamshire, UK). Tissue renin concentration was measured by radioimmunoassay as described previously (32). Bilirubin, alanine amino transferase, bile acids, albumin, and creatinine were analyzed using an analyzer (Cobas Mira; Roche Diagnostics, Basel, Switzerland). Platelet count, leucocytes, hematocrit, and hemoglobin were analyzed on a Celltac{alpha} MEK-6108K (Nihon Kohden, Tokyo, Japan). Electrolytes were determined by flame photometry (IL 943 flame photometer; Instrumentation Laboratory, Milan, Italy). Osmolality was measured by freezing point depression (Osmomat 030D; Gonotec, Berlin, Germany). Sodium and potassium balances were calculated as the ratio between oral intake and the sum of losses in urine and feces. To estimate fecal water content, feces were heated until constant weight (24 h) at 100°C. Dried feces were then dissolved in 30 ml of 0.7 M HNO3, homogenized (Polytron PT300, Kinematica, Kriens-Luzern, Switzerland), and gently shaken for 24 h. Subsequently, electrolytes were determined in the supernatant by flame photometry. Creatinine clearance (Clcrea), which is a reliable measure of glomerular filtration rate (GFR) in Wistar rats (40), was calculated using urine collected over the last 24 h in a metabolic cage.

Isolation of RNA and Ribonuclease Protection Assay

Total RNA was isolated from rat organs with the Qiagen RNeasy Midi Kit, and mRNA levels were estimated by A/T1 ribonuclease protection assay (30, 36). Plasmids carrying sequences for renin (234 bp) and 11beta-HSD-2 (291 bp) have previously been cloned and validated (22, 30). Partial rat cDNA encoding epithelial sodium channel (ENaC) subunits was cloned by RT-PCR with the following primer sequences (Invitrogen, Paisley, Scotland): {alpha}-subunit, S 5'-ATTGACCTAGACCTTCAC-3' as 5'-CAT GCGGTTGTGTTTGGA-3' (accession no. U54700, 263 bp; probe used for RNase protection assay, 193 bp); beta-subunit, 5'-AGGCTACACCTACAAGGA-'3 as 5'-AGTTCATGGTCTTGAAGC-'3 (accession no. U35175, 222 bp); and {gamma}-subunit, 5'-GCTATTCTGCCGAAGAAC-3' as 5'-TGGAGGTGCTGAGGATGG-3' (accession no. U37540, 146 bp). Primers were designed to anneal in regions without homology and were synthesized with restriction sites for BamHI (sense) and EcoRI (antisense) in the 5' direction (+15 bp) to allow for directional cloning in vector pSP73 (Promega, Rødovre, Denmark). Plasmids were sequenced by T7 polymerase (Promega) on an ABI Prism genetic analyzer with ready reaction mix from ABI. Plasmids were linearized with HindIII and purified with a Qiagen PCR purification kit. Plasmids yielded radiolabeled antisense cRNA transcripts by incubation with SP6 polymerase (Promega) and [{alpha}-32P]GTP (Amersham) according to the Promega riboprobe in vitro transcription protocol.

Western Immunoblot Analysis

Protein was isolated from distal colon and kidney as described previously (30). Protein concentration was determined on a spectrophotometer (Bio-Rad protein assay reagent). Protein separation and immunoblotting for 11beta-HSD-2 was as described previously (30).

Immunohistochemical Staining for Renin, 11beta-HSD-2, and ENaC {alpha}-Subunit

In all three series, a limited number of sham and BDL rats were fixed by retrograde perfusion of the aorta with 4% paraformaldehyde. Tissue blocks incubated overnight in paraformaldehyde and were embedded in paraffin using standard techniques. Sections (5 µm) were cut, deparaffinized, brought to a watery medium through successive alcohol-buffer mixtures, and labeled with primary antibodies [rabbit anti-rat renin (K. Poulsen, diluted 1:500); sheep anti-rat 11beta-HSD-2 (Ab 1296, Santa Cruz Biotechnology, diluted 1:2,000); rabbit anti-ENaC {alpha}-subunit (ENaCa11A, Biotrend, Köln, Germany)]. Secondary antibodies were horseradish peroxidase coupled with goat anti-rabbit immunoglobulin G (Sigma) and rabbit anti-sheep IgG (Sigma), both diluted 1:500. The sections were stained with diaminobenzidine (DAB+ substrate-chromogen system; DAKO, Glostrup, Denmark). Negative controls were without primary antibody.

Measurement of 11beta-HSD-2 Activity

11beta-HSD-2 is a unidirectional dehydrogenase catalyzing the rapid conversion of active corticosterone to inert 11-dehydrocorticosterone in the presence of NAD+. 11beta-HSD-2 activity was measured in protein homogenates from renal cortex and distal colon. Protein concentration was quantified colorimetrically using a Bio-Rad protein assay kit. Protein homogenates from kidney (25 µg/ml) and colon (50 µg/ml) were incubated in duplicate at 37°C in 0.1 M Tris buffer, pH 7.6, 0.25 M sucrose, and 5 mM MgCl2 solution with NAD+ (0.5 mM), [3H]corticosterone (10 nM), and unlabeled corticosterone (990 nM) in the presence of 10 mM DTT (19). After 60 (kidney) and 240 min (colon), the reaction was terminated by the addition of ethyl acetate, and the organic phase was reduced to dryness under a stream of oxygen-free nitrogen; steroids in the dried residue were dissolved in the mobile phase (60:15:25 water-acetonitrile-methanol) and quantified by HPLC with online liquid scintillation counting as described previously (27). Conditions were optimized for each tissue to ensure first-order kinetics.

Statistical Methods

Differences between two groups were analyzed using an unpaired t-test, and variance was tested with an F-test. Differences between more than two groups were estimated by ANOVA (treatment-series, BDL rats). If data did not have a Gaussian distribution, a Mann-Whitney U-test was used to test differences between two groups, and differences between more than two groups were estimated with the Kruskal-Wallis test. Levels of significance were P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Characterization of Experimental Model of BDL in Rats

Five weeks after BDL, all rats displayed jaundice with elevated bilirubin and hepatosplenomegaly (Tables 1 and 2). Weight gain was slowed significantly by BDL in all series, and organ weight-to-body weight ratios were significantly higher in both compensated and decompensated BDL rats compared with sham rats (Tables 1 and 2). Histopathological examination of the livers after 5 wk of BDL showed fibrosis and septa formation between portal triads and the central veins with apparently normal liver tissue in between. Seven weeks after BDL, the livers exhibited completely distorted architecture with small regeneration nodules and severe fibrosis. About 80% of the rats accumulated ascites between 5 and 7 wk after BDL (Table 1). This was associated with a mortality of ~35%. In the decompensated stage at 7 wk, plasma hemoglobin, erythrocyte volume fraction, and thrombocytes were lower, whereas the white blood cell count was elevated (Table 2). Serum albumin concentration was lower in BDL rats, whereas serum bilirubin was higher in all BDL groups compared with the sham group (Table 2). Experimental BDL thus led to progressive histopathological changes in liver compatible with cholestasis, which was associated with biochemical signs of functional liver impairment, extracellular volume expansion, and ascites.


View this table:
[in this window]
[in a new window]

  		Table 1. Basal characteristics of BDL and sham rats after 5 and 7 wk

 

View this table:
[in this window]
[in a new window]

  		Table 2. Effect of dexamethasone and K-canrenoate on organ weights, plasma electrolytes, blood cells, hormones, and Na+/K+ ratios in BDL compared with sham rats

 
Effect of BDL on Renin-Angiotensin-Aldosterone and Corticosterone in Plasma and Tissue

In sham-operated control rats, plasma renin concentration (PRC) was not different 5 and 7 wk after surgery (Fig. 1A). Whereas there was an age-dependent decline in renocortical renin mRNA expression between 5 and 7 wk, kidney renin mRNA expression was not significantly different in BDL rats compared with control. After 5 wk, the control was 100 ± 12.6% and BDL was 96.1 ± 18.3%, and after 7 wk, the control was 100 ± 13.9% and BDL was 87.5 ± 21.0%. In the BDL rats, PRC was significantly higher than controls at 5 wk but fell to control level at 7 wk. There was no obvious difference in the distribution pattern of renin-positive cells along afferent arterioles from BDL rats at 7 wk compared with sham (data not shown). The plasma aldosterone concentration was significantly elevated after BDL for 7 wk, whereas corticosterone concentrations were not significantly affected compared with sham-operated controls (Fig. 1B). Urinary Na+/K+ ratio and plasma K+ level were significantly decreased after 7 wk BDL in series 2 (BDL 0.29 ± 0.06 vs. sham 0.48 ± 0.02, P < 0.01; and BDL 5.0 ± 0.2 vs. 5.6 ± 0.2 mM control, P < 0.005, respectively), indicating mineralocorticoid excess.


Figure 1
View larger version (10K):
[in this window]
[in a new window]

  		Fig. 1. Effect of bile duct ligation (BDL) on the renin-angiotensin aldosterone system. A: plasma renin concentrations in rats followed for 5 and 7 wk (W). Values are means ± SE *P < 0.05. B: plasma concentrations of corticosterone and aldosterone after 7 wk compared with sham-operated controls (sham). Values are means ± SE. **P < 0.05 vs. control.

 
Effect of BDL on Tissue Expression Level and Cellular Distribution of 11beta-HSD-2 in Kidney and Distal Colon of Compensated and Decompensated Rats

Next, we explored whether 11beta-HSD-2 was changed by BDL in kidney and distal colon. Renocortical 11beta-HSD-2 mRNA expression was not significantly different from sham controls at 5 wk after surgery; the control was 100 ± 8.7% and BDL was 97 ± 13.8%. In contrast, after 7 wk of BDL, renocortical 11beta-HSD-2 mRNA, protein, and activity levels were significantly lower compared with those of sham rats (Fig. 2, A–C). Immunostaining of sham-control kidney sections for 11beta-HSD-2 displayed labeling associated with distal convoluted tubules, connecting tubules, and collecting ducts in cortex, whereas labeling of collecting ducts declined progressively in outer medulla and was absent in inner medulla and papilla, as previously described (Fig. 2D) (19, 30). Intercalated cells in the collecting ducts were not labeled. The overall distribution of 11beta-HSD-2 labeling in kidney from BDL rats was similar, albeit with consistently less intensity (Fig. 2D). In marked contrast to kidney, we found that 11beta-HSD-2 mRNA levels were significantly increased in distal colon after 7 wk of BDL (Fig. 3A). Indeed, 11beta-HSD-2 mRNA expression was threefold elevated in distal colon in the compensated phase after 5 wk of BDL; control was 100 ± 16.9% and BDL was 302 ± 77.5%. The mRNA findings were supported by immunolabeling (Fig. 3C); however, there was no significant difference at the protein level as shown by Western immunoblotting (Fig. 3B). 11beta-HSD-2 activity was low in distal colon compared with kidney, and hardly any conversion was detectable in either cirrhotic or control rats.


Figure 2
View larger version (54K):
[in this window]
[in a new window]

  		Fig. 2. Effect of 7 wk of BDL on 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD-2) and epithelial sodium channel (ENaC) in kidney cortex. A–C: renocortical expression of 11beta-HSD-2 mRNA (A) and protein (B) and 11beta-HSD-2 activity (C) compared with sham rats. Bars represent means ± SE. *P < 0.05 vs. sham; n = 8–12 for RNA measurements, n = 4 for protein determination, and n = 6–7 for activity assay. D: distribution of immunoreactive 11beta-HSD-2 protein in kidney sections. Labeling was associated with connecting tubules and cortical and outer medullary collecting ducts in sham rats (left), and staining was less intense in decompensated BDL rats (right). Bar, 50 µm. E: results of a ribonuclease protection assay for ENaC {alpha}-, beta-, and {gamma}-subunit mRNAs in kidney cortex from sham and BDL rats. F: quantitative evaluation of the protection assay in which ENaC subunit mRNAs in BDL rats (filled bars, n = 8) were compared with those in sham rats (open bars, n = 12). Bars represent mean ± SE counts per minute. *P < 0.05. G: distribution of immunoreactive ENaC {alpha}-subunit protein in BDL kidney (right) compared with kidney from sham rat (left). Top, immunoreactive protein visualized with diaminobenzidine (DAB+) as chromogen substrate; bottom, micrographs with fluorescence detection.

 

Figure 3
View larger version (56K):
[in this window]
[in a new window]

  		Fig. 3. Effect of 7 wk of BDL on 11beta-HSD-2 and ENaC in distal colon. A and B: 11beta-HSD-2 mRNA (A) and protein levels (B) in distal colon in BDL rats (n = 5) compared with sham rats (n = 5). Bars represent means ± SE. {dagger}P < 0.01 vs. sham. C: distribution of immunoreactive 11beta-HSD-2 protein in distal colon. Immunoreactivity for 11beta-HSD-2 was associated with cytoplasm of surface epithelial cells in BDL rats and in single cells in the colon crypts (BDL), whereas labeling was hardly detectable in sham rats. D, top: results of a ribonuclease protection assay for ENaC subunit mRNAs in distal colon from sham and BDL rats. The penultimate lane shows that the RNA probe was completely digested in the absence of target mRNA (yeast tRNA was used instead), and the last lane shows intact probes. Bottom, quantitative evaluation of the protection assay where ENaC subunit mRNAs from BDL rats (filled bars, n = 5) were compared with those from sham rats (open bars, n = 6). Bars represent mean ± SE counts per minute. *P < 0.05; **P < 0.01. E: distribution of immunoreactive ENaC {alpha}-subunit protein in distal colon from BDL rat (right) compared with distal colon from sham rat (left). Top, immunoreactive protein visualized with DAB+ as chromogen substrate; bottom, micrographs with fluorescence detection.

 
Effect of BDL on Expression and Distribution of ENaC in Kidney and Distal Colon

To explore whether the change in 11beta-HSD-2 level in kidney and perhaps colon had functional consequences, we determined mRNA level and cellular localization of the key MR-regulated target, the ENaC. In kidney cortex, all three ENaC subunits were detected at significant levels. In BDL, mRNA encoding the beta-subunit of ENaC was significantly reduced in abundance, whereas expression of {alpha}- and {gamma}-subunits was unchanged (Fig. 2, E and F). In sham rats, only the {alpha}-subunit was reproducibly detected in distal colon with the use of 40 µg of total RNA for the hybridization. In contrast to kidney, mRNA abundances for all three ENaC subunits were significantly enhanced in distal colon of decompensated BDL rats (Fig. 3D). Immunolabeling of kidney and distal colon sections with an {alpha}ENaC subunit-specific antibody showed a distinct distribution of immunoreactive protein that was similar to that observed with the 11beta-HSD-2 antibody. Thus, in kidney, {alpha}ENaC labeling was associated with distal convoluted tubules, cortical collecting ducts, and outer medullary collecting ducts (Fig. 2G). There were no obvious differences in distribution of immunoreactivity between sham and kidneys from BDL rats, but there was a clear tendency that labeling signals were weaker in the BDL kidneys (Fig. 2G). In distal colon, we did not detect any significant immunolabeling signals for {alpha}ENaC associated with epithelium or other layers in sham-operated rats, whereas {alpha}ENaC immunoreactivity and fluorescence were observed in crypt and surface epithelial cells in distal colon from the decompensated BDL rats (Fig. 3E).

Effect of Dexamethasone and K-Canrenoate on Electrolyte and Water Balance in Decompensated BDL Rats

In the next experiments, we tested whether the significant changes in 11beta-HSD-2 in kidney resulted in glucocorticoid-mediated effects on sodium balance. Dexamethasone, which has a very low affinity for MR compared with corticosterone, suppressed endogenous plasma corticosterone (Fig. 4D). The effect of dexamethasone on Na+, K+, and water balance in decompensated BDL rats was compared with the effect of K-canrenoate, an MR antagonist. Dexamethasone prevented the development of ascites as efficiently as K-canrenoate (Fig. 4A) and significantly reduced the volume of ascites (Fig. 4B). Plasma ANP concentration reflects changes in extracellular volume; it was significantly higher in the decompensated BDL group compared with sham controls and decreased significantly after treatment with both dexamethasone and K-canrenoate (Fig. 4C). Plasma renin and aldosterone concentrations were not affected by dexamethasone or K-canrenoate administration to BDL rats (Table 2). Next, we performed balance studies by analyzing intake and fecal and renal excretion of electrolytes and water (Table 3). By using special granulated food and measuring both urinary and fecal excretions, we were able to account for 100% of sodium and potassium intake.


Figure 4
View larger version (16K):
[in this window]
[in a new window]

  		Fig. 4. Effect of dexamethasone and K-canrenoate on extracellular volume parameters in BDL rats. A: effect of dexamethasone (Dex) and K-canrenoate (Can) on the incidence of ascites 7 wk after BDL. Bars represent the number of rats; filled sections indicate the number of rats with ascites. B: effect of Dex and Can on ascites volume in BDL rats after 7 wk compared with vehicle-treated BDL rats (BDL + vehicle). Individual values are shown.*P < 0.05; **P < 0.01. C: effect of Dex (n = 7) and Can (n = 9) on plasma concentration of atrial natriuretic peptide (ANP) in decompensated BDL rats after 7 wk. Bars represent means ± SE. *P < 0.05 vs. BDL + vehicle. D: effect of Dex (n = 7) and Can (n = 9) on plasma corticosterone concentration in BDL rats after 7 wk. Bars represent means ± SE. *P < 0.05 vs. BDL + vehicle.

 

View this table:
[in this window]
[in a new window]

  		Table 3. Effect of dexamethasone and K-canrenoate on the time courses for intake and renal and fecal excretion of sodium and potassium in BDL rats

 
Sodium. Sham control rats were in sodium balance (intake of 680 ± 16 µmol Na+·100 g rat–1·24 h–1), and they excreted 85% of the daily sodium intake in the urine and 15% in feces (Fig. 5, A–C). In contrast, the BDL rats at 7 wk were in positive sodium balance (Fig. 5A). This was the result of a significant decrease in the urinary sodium excretion to 55% of the intake (Fig. 5B), which was not counteracted by any significantly increased fecal sodium loss: 23% of intake (Fig. 5C). Treatment with dexamethasone or K-canrenoate did not affect sodium intake in the cirrhotic rats (Table 3). At baseline before intervention, the three groups of BDL rats had similar electrolyte excretion. Treatment with dexamethasone or K-canrenoate increased total sodium excretion significantly to 148 ± 19 and 139 ± 12% of intake, respectively, in the first 24 h after the intervention (Table 3). After 48 h, sodium excretion was increased to the same level as sham rats (sham + vehicle, 99 ± 4.5%; BDL + vehicle, 84 ± 15%; BDL + dexamethasone, 110 ± 28%; BDL + K-canrenoate, 91 ± 25%) (Table 3). The effect of intervention on sodium handling was different in kidneys and intestine. Urinary sodium excretion was increased by treatment with both dexamethasone and K-canrenoate (Fig. 5B), whereas the fecal sodium loss decreased in the dexamethasone group but not after K-canrenoate-treatment (Fig. 5C). Thus dexamethasone stimulated intestinal sodium absorption in BDL rats.


Figure 5
View larger version (33K):
[in this window]
[in a new window]

  		Fig. 5. Effect of dexamethasone and K-canrenoate on sodium, potassium, and water balances in BDL rats. A and D: total sodium and potassium balances were determined 7 wk after surgery in vehicle-treated BDL and sham rats, Dex-treated BDL rats, and Can-treated BDL rats. B and C: urinary (B) and fecal (C) sodium excretion was determined 7 wk after surgery in vehicle-treated BDL and sham rats, Dex-treated BDL rats, and Can-treated BDL rats. E and F: urinary (E) and fecal (F) potassium excretion was determined 7 wk after surgery in vehicle-treated BDL and sham rats; Dex-treated BDL rats, and Can-treated BDL rats. G and H: water intake (G) and urine flow (H) were determined 7 wk after surgery in vehicle-treated BDL and sham rats, Dex-treated BDL rats, and Can-treated BDL rats. All bars represent means ± SE from averages over the 5-day period. Numbers of rats in each group are as reported in Fig. 4 legend. *P < 0.05; **P < 0.01.

 
Potassium. The sham control rats were in potassium balance (Fig. 5D). The decompensated group had a negative potassium balance, indicating excess MR activation. Potassium loss was caused by higher fecal loss, whereas urinary potassium excretion was not different from control level. The fecal potassium loss was decreased by treatment with K-canrenoate but not dexamethasone (Fig. 5F). Of note, renal handling of potassium was similar in all four groups and unaffected by treatments (Fig. 5E). Thus excess potassium wasting occurred exclusively through fecal losses in BDL rats. The time courses of absolute values of potassium intake and outputs are shown in Table 3.

Water. Renal water excretion was similar in control and decompensated 7-wk BDL groups but increased significantly after treatment of the decompensated rats with dexamethasone or K-canrenoate (Fig. 5H). Only the K-canrenoate-treated group increased water intake (P < 0.05) (Fig. 5G). The water content in feces was similar in the sham + vehicle (57 ± 0.5%), BDL + vehicle (58 ± 0.7%), BDL + dexamethasone (57 ± 0.8%), and BDL + K-canrenoate rats (55 ± 0.4%). As a consequence of a larger food intake, fecal water loss was significantly higher in the sham + vehicle rats (1.7 ± 0.04 ml·100 g rat–1·24 h–1) compared with the three BDL groups that had identical fecal water losses (1.1 ± 0.1 ml·100 g rat–1·24 h–1; P < 0.01).

Effect of Dexamethasone and K-Canrenoate on Urinary and Feces Na+/K+ Concentration Ratios

The urinary Na+/ K+ ratio was significantly lower in decompensated BDL rats compared with sham-operated controls (Fig. 6A). Treatment of the BDL rats with dexamethasone or K-canrenoate led to a significant increase in urinary Na+/ K+ ratio to a level not different from that of sham-operated controls. Feces Na+/ K+ ratio was also significantly reduced in the BDL rats compared with sham-operated controls. Treatment with dexamethasone led to a further reduction of the feces Na+/ K+ ratio, whereas treatment with K-canrenoate led to a significant increase in Na+/K+ ratio compared with the decompensated BDL + vehicle rats (Fig. 6B).


Figure 6
View larger version (21K):
[in this window]
[in a new window]

  		Fig. 6. Effect of dexamethasone and K-canrenoate on urinary and fecal Na+/K+ ratio in BDL rats. A: effect of Dex and Can on urinary Na+/K+ ratio in BDL compared with sham rats. B: effect of Dex and Can on fecal Na+/K+ ratio in BDL rats compared with sham rats. Values are shown as means ± SE. Numbers of rats in each group are as reported in Fig. 4. *P < 0.05; **P < 0.01.

 
Effect of Dexamethasone and K-Canrenoate on Plasma and Urine Osmolality and Creatinine Clearance in Decompensated BDL Rats

Plasma osmolalities were similar in all groups (sham + vehicle, 296 ± 1.2 mosmol/kgH2O; BDL + vehicle, 297 ± 1.2 mosmol/kgH2O; BDL + dexamethasone, 296 ± 0.3 mosmol/kgH2O; BDL + K-canrenoate, 298 ± 0.8 mosmol/kgH2O). Urine osmolality decreased significantly in the K-canrenoate-treated group as expected from the increase in water excretion (BDL + canrenoate, 0.8 ± 0.1 mosmol/kgH2O, compared with sham + vehicle, 1.6 ± 0.1 mosmol/kgH2O, P < 0.05; BDL + vehicle, 1.5 ± 0.2 mosmol/kgH2O, and BDL + dexamethasone, 1.5 ± 0.2 mosmol/kgH2O). Osmolar clearance (Closm) was lower in the BDL + vehicle compared with the sham + vehicle group (12.0 ± 1.3 vs. 16.7 ± 1.2 µl/min, P < 0.05). Closm increased to the control level after dexamethasone and K-canrenoate (17.7 ± 0.7 and 15.1 ± 0.5 µl/min, respectively). Clcrea was higher in the sham + vehicle group (0.30 ± 0.03 ml·min–1·100 g body wt–1) than in the decompensated BDL + vehicle group (0.20 ± 0.03 ml·min–1·100 g body wt–1). In the dexamethasone-treated BDL group, Clcrea was increased to 0.32 ± 0.03 ml·min–1·100 g body wt–1, whereas in the K-canrenoate-treated BDL group, Clcrea was unchanged (0.25 ± 0.03 ml·min–1·100 g body wt–1).

Effect of Dexamethasone and K-Canrenoate on Weight Gain, Organ Weights, and Blood Chemistry

Treatment with dexamethasone or K-canrenoate did not correct the significantly slower rate of growth of BDL rats. The dexamethasone-treated BDL rats actually had a significantly lower weight at completion of the study compared with the K-canrenoate-treated BDL rats despite a similar food intake and natriuretic effect (Table 2). This was probably caused by the overall catabolic effect of the potent glucocorticoid. The organ weight-to-body weight ratios in the decompensated BDL rats remained or were further elevated after treatment with K-canrenoate or dexamethasone compared with sham controls. Hemoglobin and erythrocyte volume fractions were lower in the vehicle-treated BDL and K-canrenoate-treated BDL groups but increased in the dexamethasone-treated BDL group (Table 2). Plasma sodium and creatinine levels were equal in all groups (Table 2). Plasma bilirubin concentration was similar in BDL rats and in the BDL rats treated with K-canrenoate and dexamethasone.


   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
In the present study, we used the rat model of BDL to study mechanisms of sodium and water retention in the transition from compensated to decompensated liver cirrhosis. The data showed that augmented renal sodium reabsorption was responsible for a positive sodium balance despite increased fecal sodium losses. The enzyme 11beta-HSD-2 was downregulated in kidney, and suppression of endogenous corticosterone by treatment with dexamethasone corrected the decreased urinary Na+/K+ ratio, augmented urinary sodium excretion, and reduced ascites formation. This indicates that excess activation of the MR by corticosterone contributes to the exaggerated renal sodium reabsorption during decompensated stages of BDL.

Consistent with reports from rats with carbon tetrachloride-induced cirrhosis (12), we observed that ENaC mRNA expression in the kidney was unchanged or slightly reduced at the same time as plasma aldosterone was elevated. Increased cell surface expression of the ENaC subunits after MR activation (28) may explain the increased renal ENaC activity despite unchanged ENaC mRNA expression (2), or dysregulated expression and activity of aldosterone-induced/repressed proteins may lead to prolonged surface expression of ENaC. In a recent study, serum and glucocorticoid-inducible kinase-1, which have a central role in recruitment of ENaC to the cell surface, were unchanged in 4-wk BDL rats, whereas Nedd-4, a ubiquitin ligase protein that promotes internalization and degradation of ENaC, was reduced >50% (44). During the development of decompensation in the period from 5 to 7 wk, there was a decrease in renin synthesis and secretion, whereas plasma aldosterone concentration was significantly increased in the decompensated rats at 7 wk. This could contribute to increased sodium reabsorption.

In contrast to kidney, all ENaC subunits were markedly elevated in distal colon of BDL rats. This upregulation correlated with increased fecal potassium and sodium losses, suggesting a shift to low-capacity, high-affinity NaCl transport. Fecal NaCl excretion was decreased to control level by dexamethasone, but fecal potassium wasting was not. Thus sodium and potassium handling were differentially changed in kidney and distal colon with progression of bile duct-occlusive liver disease.

Urinary Na+/K+ ratio was decreased in the decompensated BDL rats, which indicated a MR-mediated effect on the collecting ducts. This was supported by the fact that administration of an MR antagonist, K-canrenoate, increased the urinary Na+/K+ ratio, normalized sodium balance, reduced the incidence and severity of ascites, and led to suppression of the plasma ANP concentration, which is an indicator of intravascular volume. Several mechanisms may contribute to the activation of the MR. Plasma aldosterone concentration was significantly increased after 7 wk of BDL compared with the sham-operated controls. On the other hand, there also was a significant fall in the expression of renal 11beta-HSD-2 in from 5 to 7 wk, when decompensation develops. This would allow corticosterone to gain access to renal MR. In accordance with this notion, we observed that suppression of plasma corticosterone (but not aldosterone) concentration with dexamethasone corrected the urinary Na+/K+ ratio, normalized sodium balance, reduced the incidence and severity of ascites, and suppressed plasma ANP concentration to a similar degree as direct blockade of MR with K-canrenoate. A similar effect of dexamethasone on urinary Na+/K+ ratio was observed in mice with targeted deletion of the 11beta-HSD-2 gene (25).

Dexamethasone binds to the MR in vitro with an affinity close to that of glucocorticoids (20), suggesting that dexamethasone could act as a MR antagonist. However, dexamethasone does not functionally bind to the renal MR in vivo (14, 16), probably because of a high off-rate of dexamethasone bound to the MR in contrast to the stable binding of dexamethasone to the glucocorticoid receptor (21, 34). Furthermore, the sodium transport response to dexamethasone in the mCCDcl1 cell line is not inhibited by the MR antagonist spironolactone (17). Thus a direct antagonist action of dexamethasone is less likely to explain the present results. Dexamethasone increased creatinine clearance, suggesting that an increase in GFR and tubular flow rate could increase distal potassium secretion and thereby normalize the Na+/K+ ratio. However, the absolute urinary potassium excretion was not affected by dexamethasone treatment, making this possibility less likely. Together, the data are consistent with the hypothesis that inappropriate activation of MR by corticosterone contributed to renal salt and water retention in decompensated liver cirrhosis. This confirms the functional significance of reduced renal 11beta-HSD-2 level, observed in the present study during decompensation and in previous studies during the early preascitic phase of liver impairment (1, 10, 23, 24). Inhibition of 11beta-HSD-2 may be mediated by the high concentration of bile acids (1, 31, 33, 37) or other processes. However, it is interesting that the process was fairly specific for the nephron and affected 11beta-HSD-2 mRNA and protein levels as well as enzyme activity. In this line, licorice-based inhibitors have been suggested to downregulate 11beta-HSD gene transcription, although the molecular mechanism is moot. This raises the intriguing possibility that treatments to induce renal 11beta-HSD-2 activity as well as those that block cortisol production may be useful in hepatic failure-induced sodium and water retention.

Distal colon is another target for mineralocorticoids that has not previously been investigated in the context of the BDL model. The total balance studies showed a marked increase in fecal NaCl losses after BDL, and in contrast to the kidney, 11beta-HSD-2 mRNA expression was significantly upregulated in colon, whereas protein levels were unchanged. In addition, we found an increased expression of ENaC as also observed in the colon of portal vein-ligated rats (13). It has been hypothesized that downregulation of renal 11beta-HSD-2 activity in liver cirrhosis could be mediated by the high plasma concentration of bile acids (1, 31, 33). The predominant mechanism of sodium reabsorption in the normal distal rat colon is a low-affinity, high-capacity electroneutral sodium transport through combined Na+/H+ and Cl–/HCO3– exchangers that are stimulated by glucocorticoids (4). In conditions with increased MR activation, the transport mechanism of distal colon changes from the low-affinity, high-capacity electroneutral sodium transport to a high-affinity, low-capacity transport through ENaC (5). The increased expression of ENaC in BDL rats is consistent with such a transition. The electrogenic transport through ENaC varies as a function of mineralocorticoid status. Increased activation of ENaC results in a lumen-negative potential, which favors leak of potassium back into the lumen. This also is consistent with the observed 50% decrease in intestinal sodium absorption in the cirrhotic rats and with the stimulation of intestinal sodium absorption by dexamethasone, which stimulates glucocorticoid receptors. In keeping with this interpretation, dexamethasone did not correct the intestinal potassium loss. The increased ENaC expression in colon of decompensated rats was associated with a higher potassium loss into feces as one would predict from the transport characteristics. This finding could explain the lower plasma potassium concentration, which was not explained by potassium loss in the urine. In keeping with this, intestinal potassium loss, but not sodium loss, was corrected by treatment with K-canrenoate. Thus, under the conditions investigated in the present study, changes in intestinal potassium transport account fully for the effects on total potassium homeostasis in BDL rats.

We conclude that development of liver cirrhosis in the BDL rat is associated with sequential changes in the renin-angiotensin-aldosterone system, but our results suggest that renal downregulation of 11beta-HSD-2 and inappropriate activation of sodium absorption by glucocorticoids plays a major functional role for development of overt decompensation. In addition, our results point to an unexpected regulatory role of colon for potassium and sodium homeostasis in liver cirrhosis.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
This work was supported by the Institute of Clinical Research, Odense University Hospital, Denmark, the Danish Society of Hypertension, the Danish Society of Nephrology, the Novo Nordisk Foundation, The Danish Heart Foundation, the Wellcome Trust, and the Danish Medical Research Council.


   ACKNOWLEDGMENTS
 
We thank Mette Svendsen, Dina Dræby, Inge Andersen, Lis Teusch, Mette Fredenslund, Karin Kejling, and Bodil Kristensen for technical assistance and Anthony M. Carter for language revision.


   FOOTNOTES
 

Address for reprint requests and other correspondence: O. Skøtt, Physiology and Pharmacology, Winsloewparken 21.3, DK-5000 Odense C, Denmark (e-mail: oskott{at}health.sdu.dk)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Ackermann D, Vogt B, Escher G, Dick B, Reichen J, Frey BM, Frey FJ. Inhibition of 11beta-hydroxysteroid dehydrogenase by bile acids in rats with cirrhosis. Hepatology 30: 623–629, 1999.[CrossRef][ISI][Medline]
  2. Alvarez de la Rosa D, Paunescu TG, Els WJ, Helman SI, Canessa CM. Mechanisms of regulation of epithelial sodium channel by SGK1 in A6 cells. J Gen Physiol 124: 395–407, 2004.[Abstract/Free Full Text]
  3. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 38, Suppl 1: S69–S89, 2003.
  4. Bastl CP, Schulman G, Cragoe EJ Jr. Low-dose glucocorticoids stimulate electroneutral NaCl absorption in rat colon. Am J Physiol Renal Fluid Electrolyte Physiol 257: F1027–F1038, 1989.[Abstract/Free Full Text]
  5. Binder HJ, Foster ES, Budinger ME, Hayslett JP. Mechanism of electroneutral sodium chloride absorption in distal colon of the rat. Gastroenterology 93: 449–455, 1987.[ISI][Medline]
  6. Cameron GR, Hasan SM. Disturbances of structure and function in the liver as the result of biliary obstruction. J Pathol Bacteriol 75: 333–349, 1958.[CrossRef][ISI][Medline]
  7. Chonko AM, Bay WH, Stein JH, Ferris TF. The role of renin and aldosterone in the salt retention of edema. Am J Med 63: 881–889, 1977.[CrossRef][ISI][Medline]
  8. Dagher L, Moore K. The hepatorenal syndrome. Gut 49: 729–737, 2001.[Free Full Text]
  9. Emmeluth C, Drummer C, Gerzer R, Bie P. Natriuresis in conscious dogs caused by increased carotid [Na+] during angiotensin II and aldosterone blockade. Acta Physiol Scand 151: 403–411, 1994.[ISI][Medline]
  10. Escher G, Nawrocki A, Staub T, Vishwanath BS, Frey BM, Reichen J, Frey FJ. Down-regulation of hepatic and renal 11beta-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology 114: 175–184, 1998.[CrossRef][ISI][Medline]
  11. Farman N, Rafestin-Oblin ME. Multiple aspects of mineralocorticoid selectivity. Am J Physiol Renal Physiol 280: F181–F192, 2001.[Abstract/Free Full Text]
  12. Fernandez-Llama P, Ageloff S, Fernandez-Varo G, Ros J, Wang X, Garra N, Esteva-Font C, Ballarin J, Barcelo P, Arroyo V, Stokes JB, Knepper MA, Jimenez W. Sodium retention in cirrhotic rats is associated with increased renal abundance of sodium transporter proteins. Kidney Int 67: 622–630, 2005.[CrossRef][ISI][Medline]
  13. Fraser GM, Blendis LM, Smirnoff P, Sikular E, Niv Y, Schwartz B. Portal hypertension induces sodium channel expression in colonocytes from the distal colon of the rat. Am J Physiol Gastrointest Liver Physiol 279: G886–G892, 2000.[Abstract/Free Full Text]
  14. Funder JW, Feldman D, Edelman IS. The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 92: 994–1004, 1973.[ISI][Medline]
  15. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242: 583–585, 1988.[Abstract/Free Full Text]
  16. Funder JW, Sheppard K. Adrenocortical steroids and the brain. Annu Rev Physiol 49: 397–411, 1987.[CrossRef][ISI][Medline]
  17. Gaeggeler HP, Gonzalez-Rodriguez E, Jaeger NF, Loffing-Cueni D, Norregaard R, Loffing J, Horisberger JD, Rossier BC. Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line. J Am Soc Nephrol 16: 878–891, 2005.[Abstract/Free Full Text]
  18. Girgrah N, Liu P, Collier J, Blendis L, Wong F. Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis. Gut 46: 114–120, 2000.[Abstract/Free Full Text]
  19. Gomez-Sanchez EP, Ganjam V, Chen YJ, Liu Y, Zhou MY, Toroslu C, Romero DG, Hughson MD, de Rodriguez A, Gomez-Sanchez CE. Regulation of 11beta-hydroxysteroid dehydrogenase enzymes in the rat kidney by estradiol. Am J Physiol Endocrinol Metab 285: E272–E279, 2003.[Abstract/Free Full Text]
  20. Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AF, Diederich S, Bahr V. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol 151: 397–406, 2004.[Abstract]
  21. Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett 464: 9–13, 1999.[CrossRef][ISI][Medline]
  22. Jensen BL, Kurtz A. Differential regulation of renal cyclooxygenase mRNA by dietary salt intake. Kidney Int 52: 1242–1249, 1997.[ISI][Medline]
  23. Kim SW, Schou UK, Peters CD, de Seigneux S, Kwon TH, Knepper MA, Jonassen TE, Frokiaer J, Nielsen S. Increased apical targeting of renal epithelial sodium channel subunits and decreased expression of type 2 11beta-hydroxysteroid dehydrogenase in rats with CCl4-induced decompensated liver cirrhosis. J Am Soc Nephrol 16: 3196–3210, 2005.[Abstract/Free Full Text]
  24. Kim SW, Wang W, Sassen MC, Choi KC, Han JS, Knepper MA, Jonassen TE, Frokiaer J, Nielsen S. Biphasic changes of epithelial sodium channel abundance and trafficking in common bile duct ligation-induced liver cirrhosis. Kidney Int 69: 89–98, 2006.[CrossRef][ISI][Medline]
  25. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest 103: 683–689, 1999.[ISI][Medline]
  26. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 65: 305–311, 1984.[ISI][Medline]
  27. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141: 560–563, 2000.[Abstract/Free Full Text]
  28. Loffing J, Zecevic M, Feraille E, Kaissling B, Asher C, Rossier BC, Firestone GL, Pearce D, Verrey F. Aldosterone induces rapid apical translocation of ENaC in early portion of renal collecting system: possible role of SGK. Am J Physiol Renal Physiol 280: F675–F682, 2001.[Abstract/Free Full Text]
  29. Lykkegard S, Poulsen K. Ultramicroassay for plasma renin concentration in the rat using the antibody-trapping technique. Anal Biochem 75: 250–259, 1976.[CrossRef][ISI][Medline]
  30. Norregaard R, Uhrenholt TR, Bistrup C, Skott O, Jensen BL. Stimulation of 11beta-hydroxysteroid dehydrogenase type 2 in rat colon but not in kidney by low dietary NaCl intake. Am J Physiol Renal Physiol 285: F348–F358, 2003.[Abstract/Free Full Text]
  31. Perschel FH, Buhler H, Hierholzer K. Bile acids and their amidates inhibit 11beta-hydroxysteroid dehydrogenase obtained from rat kidney. Pflügers Arch 418: 538–543, 1991.[CrossRef][ISI][Medline]
  32. Poulsen K. Measurements of renin-angiotensin-aldosterone. Pharmacol Rev 25: 249–257, 1973.[Free Full Text]
  33. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. Reduced activity of 11beta-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest 108: 1299–1305, 2001.[CrossRef][ISI][Medline]
  34. Reul JM, Gesing A, Droste S, Stec IS, Weber A, Bachmann C, Bilang-Bleuel A, Holsboer F, Linthorst AC. The brain mineralocorticoid receptor: greedy for ligand, mysterious in function. Eur J Pharmacol 405: 235–249, 2000.[CrossRef][ISI][Medline]
  35. Rosoff L Jr, Zia P, Reynolds T, Horton R. Studies of renin and aldosterone in cirrhotic patients with ascites. Gastroenterology 69: 698–705, 1975.[ISI][Medline]
  36. Schricker K, Hamann M, Kurtz A. Nitric oxide and prostaglandins are involved in the macula densa control of the renin system. Am J Physiol Renal Fluid Electrolyte Physiol 269: F825–F830, 1995.[Abstract/Free Full Text]
  37. Stauffer AT, Rochat MK, Dick B, Frey FJ, Odermatt A. Chenodeoxycholic acid and deoxycholic acid inhibit 11beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem 277: 26286–26292, 2002.[Abstract/Free Full Text]
  38. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 2: 821–824, 1987.[ISI][Medline]
  39. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, Bradlow HL, New MI. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 49: 757–764, 1979.[Abstract]
  40. Van Liew JB, Zamlauski-Tucker MJ, Feld LG. Endogenous creatinine clearance in the rat: strain variation. Life Sci 53: 1015–1021, 1993.[CrossRef][ISI][Medline]
  41. Wernze H, Spech HJ, Muller G. Studies on the activity of the renin-angiotensin-aldosterone system (RAAS) in patients with cirrhosis of the liver. Klin Wochenschr 56: 389–397, 1978.[CrossRef][ISI][Medline]
  42. Wilkinson SP, Jowett TP, Slater JD, Arroyo V, Moodie H, Williams R. Renal sodium retention in cirrhosis: relation to aldosterone and nephron site. Clin Sci (Lond) 56: 169–177, 1979.[Medline]
  43. Wong F, Sniderman K, Blendis L. The renal sympathetic and renin-angiotensin response to lower body negative pressure in well-compensated cirrhosis. Gastroenterology 115: 397–405, 1998.[CrossRef][ISI][Medline]
  44. Yu Z, Serra A, Sauter D, Loffing J, Ackermann D, Frey FJ, Frey BM, Vogt B. Sodium retention in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter (NCC). Nephrol Dial Transplant 20: 1833–1841, 2005.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
E. Kompanowska-Jezierska, H. Wolff, M. Kuczeriszka, J. B. Gramsbergen, A. Walkowska, E. J. Johns, and P. Bie
Renal nerves and nNOS: roles in natriuresis of acute isovolumetric sodium loading in conscious rats
Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2008; 294(4): R1130 - R1139.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Z. Balazs, R. A.S. Schweizer, F. J. Frey, F. Rohner-Jeanrenaud, and A. Odermatt
DHEA Induces 11 -HSD2 by Acting on CCAAT/Enhancer-Binding Proteins
J. Am. Soc. Nephrol., January 1, 2008; 19(1): 92 - 101.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/1/R625    most recent
00418.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar